Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Impact of LVEF and de novo Heart Failure on Outcomes of SGLT2 Inhibitor Therapy Initiated During Acute Heart Failure
Session:
Sessão de Posters 10 - Cuidados modernos na insuficiência cardíaca: congestão, metabolismo e resultados
Speaker:
Ana Marta C. Pinto
Congress:
CPC 2026
Topic:
L. Cardiovascular Pharmacology
Theme:
31. Pharmacology and Pharmacotherapy
Subtheme:
31.1 Cardiovascular Pharmacotherapy
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Ana Marta C. Pinto; Emídio Mata; Bernardo Resende; Margarida Castro; João Português; Sílvia Ribeiro; João Gameiro; Filipa Cordeiro; Lino Gonçalves; António Lourenço
Abstract
<p>Background: Acute heart failure (AHF) carries high short-term mortality and rehospitalization despite advances in therapy. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes in chronic heart failure (HF), but their efficacy when initiated during AHF hospitalization is less clear. Effects may differ by de novo versus chronic HF and left ventricular ejection fraction (LVEF). </p> <p>Aim: To assess the efficacy of SGLT2i initiated during AHF hospitalization and examine whether LVEF or de novo HF influence outcomes. </p> <p>Methods: A systematic review and meta-analysis of RCTs was performed across five databases. Trials initiating dapagliflozin or empagliflozin during AHF hospitalization alongside standard therapy were included. Random-effects meta-analyses estimated pooled risk ratios (RRs) for all-cause mortality and HF hospitalization (HFH), and mixed-effects meta-regression evaluated the influence of LVEF and de novo HF. </p> <p>Results: Eight RCTs involving 3596 patients (1817 SGLT2i; 1779 controls) were included. The proportion of de novo HF ranged from 29.9% to 53.3%, mean LVEF was consistently ≤40%, and over half of patients were NYHA class III/IV. Initiation of SGLT2i during hospitalization significantly reduced all-cause mortality (RR 0.63[0.46–0.85] P=0.003). No significant reduction was observed for HFH (RR 0.86[0.69–1.07] P=0.78). </p> <p>Meta-regression analyses showed that neither baseline LVEF nor de novo HF prevalence significantly influenced outcomes. For all-cause mortality, the RR at LVEF 20% was 0.56[0.21–1.48], with each 10% increase in LVEF associated with a nonsignificant 9% rise in RR (1.09 [0.58–2.02] P=0.79). For HF hospitalization, the baseline RR at LVEF 20% was 0.99[0.48–2.03], with each 10% increase in LVEF linked to a nonsignificant 10% reduction in RR (0.90[0.57–1.44] P=0.67). Regarding de novo HF, the RR for all-cause mortality at 0% prevalence was 0.49[0.04–5.73], with each 10% increase in prevalence associated with a nonsignificant 6% increase in RR (1.06[0.59–1.92] P=0.84). For HF hospitalization, the baseline RR at 0% de novo HF was 2.62[0.28–24.3], and each 10% increase in prevalence was linked to a nonsignificant 23% reduction in RR (0.77 [0.46–1.30] P=0.32). </p> <p>Conclusion: Initiation of SGLT2i during hospitalization for AHF significantly reduces short-term all-cause mortality. The benefits appear consistent across patients with varying baseline LVEF and proportions of de novo heart failure, suggesting broad applicability in AHF management. </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site